Puretech Health operating losses narrow in 'landmark year'
25th Apr 2024 10:07
(Sharecast News) - Biotechnology company Puretech Health said on Thursday that 2023 had been "a landmark year" for the group, making "strong strategic and clinical progress".
Read morePureTech founder steps down as CEO to lead SeaPort spin-off
9th Apr 2024 07:48
(Sharecast News) - Clinical-stage biotherapeutics group PureTech has announced that its founding chief executive is to step down to lead SeaPort Therapeutics, a PureTech company she founded that has just raised $100m in Series A financing.
Read morePuretech Health proposes $100m capital return
19th Mar 2024 09:46
(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.
Read moreUS Royalty Pharma strikes deal with PureTech Health on KarXT royalties
23rd Mar 2023 07:24
(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.
Read morePureTech's Alkili reports success in adolescent ADHD study
6th Jan 2023 18:31
(Sharecast News) - Clinical-stage biotherapeutics investor PureTech Health announced on Friday today that its digital medicine company Akili, which it founded, announced topline results of the 'STARS-ADHD-Adolescents' label expansion study evaluating the efficacy and safety of 'EndeavorRx', or 'AKL-T01' in adolescents aged 13 to 17 with attention-deficit hyperactivity disorder (ADHD).
Read morePuretech, Nektar Therapeutics end merger talks
11th Oct 2022 07:05
(Sharecast News) - Shares in healthcare company PureTech fell on Tuesday as the company said it and US-based Nektar Therapeutics had ended merger talks only four days after they announced a potential tie up.
Read morePuretech Health confirms possible tie-up with Nektar Therapeutics
7th Oct 2022 07:10
(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.
Read morePuretech Health confirms possible tie-up with Nektar Therapeutics
7th Oct 2022 07:10
(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.
Read morePureTech first-half mixed as it makes good clinical progress
25th Aug 2022 09:25
(Sharecast News) - PureTech Health reported total first-half revenue of $7.03m on Thursday, up from $5.84m year-on-year.
Read morePureTech reports 'Glyph' milestone, disappointing long Covid results
14th Jun 2022 07:33
(Sharecast News) - PureTech Health said on Tuesday that it had met a milestone in proving its 'Glyph' therapeutic platform, while separately announcing disappointing results from a study into long Covid.
Read morePureTech to buy back up to $50m of shares
5th May 2022 10:09
(Sharecast News) - PureTech Health has announced a $50m share buyback programme, sending shares in the FTSE 250 biotech sharply higher.
Read morePuretech Health receives $100m from sale of 55% stake in Karuna Therapeutics
10th Nov 2021 09:15
(Sharecast News) - Biotechnology company Puretech Health has received approximately $100.0m in cash from the sale of a portion of the group's shares in its founded entity Karuna Therapeutics.
Read morePureTech Health's Vor wins FDA fast-track approval for cancer drug
10th Sep 2021 07:38
(Sharecast News) - Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.
Read moreTuesday broker round-up
24th Aug 2021 14:34
(Sharecast News) - Coats: Jefferies starts at buy with 97.0p target price.
Read morePureTech in 'strong' position despite swinging to net loss
24th Aug 2021 07:42
(Sharecast News) - Biotechnology company PureTech Health swung to a loss in its first half, it said on Tuesday, amid rising costs.
Read more